Trial Profile
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Pitavastatin (Primary)
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- Acronyms REPRIEVE; REPRIEVE; REPRIEVE EU
- 02 Jan 2024 Results from biomarker sub study examining associations between CMV IgG titer and physical function in virologically suppressed people with HIV , published in the JAIDS
- 13 Nov 2023 Results of REPRIEVE Mechanistic Substudy investigating statin effects on noncalcified coronary artery plaque on coronary CT angiography (CTA) and inflammatory biomarkers as potential mechanisms for prevention of MACE, presented at the American Heart Association Scientific Sessions 2023
- 01 Aug 2023 Status changed from active, no longer recruiting to completed.